Skip to main content

Table 6 Probability of achieving the cost-effectiveness thresholds

From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

cost-effectiveness threshold in GDP per capita/LY (QALY)

Probability of achieving the cost-effectiveness threshold in percent

Germany

United States

LY

QALY

LY

QALY

3

0

0

0.5

0.2

6

87.3

85.6

5.6

4.3

9

100.0

96.4

19.2

11.7

  1. GDP gross domestic product, LY life year, QALY quality-adjusted life year